港股異動 | 信達生物(1801.HK)漲超5% 獲港股通昨日淨買入13.93億港元
格隆匯9月8日丨信達生物(1801.HK)高開高走,現報60.6港元,漲5.39%,暫成交3090萬港元,最新總市值848億港元。據“醫藥魔方”消息,9月5日信達生物提交的1類新藥IBI319臨牀申請獲得CDE受理,這是信達生物申報臨牀的第5款雙抗。此外,信達生物獲納入港股通昨日生效,據格隆匯APP顯示,港股通昨日淨買入信達生物13.93億港元,居當日淨買額榜首。美銀證券近日發研報指,信達生物旗下達伯舒(信迪利單抗注射液)在最大癌症適應症中的發展勢頭強勁;且基於信達生物與禮來公司及Coherus的合作,將其目標價上調至65港元,維持“買入”評級,看好其藥物時間表及國際策略。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.